NasdaqCM:BLTEPharmaceuticals
A Look At Belite Bio (BLTE) Valuation After Phase 3 Success And Large Public Offering
Belite Bio (BLTE) drew attention after its Phase 3 DRAGON trial met the primary endpoint for Tinlarebant, alongside a US$402 million public offering that supports its planned NDA submission and early commercialization work.
See our latest analysis for Belite Bio.
The trial success and funding news sit against a share price of US$169.85, with a 7 day share price return of 11.69% but a 30 day share price return decline of 1.58%. The 1 year total shareholder return of 198.51% and 3 year total...